Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

16.22 -0.40 (-2.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,035,224
Open 16.60
Bid (Size) 15.55 (1)
Ask (Size) 18.90 (1)
Prev. Close 16.62
Today's Range 15.21 - 16.83
52wk Range 12.24 - 28.05
Shares Outstanding 161,843,185
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
 
Via Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday. 
Via Benzinga

Performance

YTD
-33.50%
-33.50%
1 Month
+1.88%
+1.88%
3 Month
-3.68%
-3.68%
6 Month
-35.46%
-35.46%
1 Year
-15.34%
-15.34%

More News

Read More
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
Via Benzinga
ACADIA Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions
Via Benzinga
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
8 Analysts Have This to Say About ACADIA Pharmaceuticals
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Via Benzinga
Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5
Via Benzinga
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate
Via Benzinga
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Where ACADIA Pharmaceuticals Stands With Analysts
Via Benzinga
Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis
Via Benzinga
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.